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In agreement with EULAR recommendations, a DMARD in combination with a biotherapy is
the reference treatment because of the superior long-term clinical and radiographic out-
comes. Methotrexate (MTX) is the cornerstone of combination therapy but is in some cases
contra-indicated or poorly tolerated. This observational study aimed to compare the effec-
tiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treat-
ment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or
more DMARDs and/or biological agents in a real-world setting.
Methods
We performed an ambispective review of 91 patients with active RA who were routinely
treated with TCZ plus MTX or LEF. A comparative study between the two combinations of
treatment was performed at 6 months of follow-up considering 3 outcomes: improvement of
RA disease activity, evolution of functional disability, and tolerability and side effect profile.
Results
Of the 91 patients, 62 received TCZ with MTX and 29 received TCZ with LEF. Eighty-one
patients were followed for 6 months, and the remaining 10 patients discontinued treatment
due to serious adverse events. At baseline, there were no significant differences between
the groups in terms of the main clinical and laboratory data or in the number of previous
DMARDs and biological agents used. At 6 months, there were no significant differences be-
tween the combinations in terms of disease activity and functional disability. Serious ad-
verse events occurred in 11% and 10% of the patients treated in combination with MTX and
LEF, respectively.
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Conclusion
Our preliminary data support the argument that LEF is an effective and safe (equivalent) al-
ternative to MTX for combination treatment with TCZ.
Introduction
Tocilizumab (TCZ) is a humanized interleukin-6 (IL-6) receptor monoclonal antibody that
competitively inhibits the binding of IL-6 to its receptor [1]. TCZ was approved in Europe in
2009 for the treatment of moderate to severe rheumatoid arthritis (RA) in patients with an in-
adequate response to one or more disease-modifying antirheumatic drugs (DMARDs) and/or
tumor necrosis factor (TNF) antagonists [2]. Moreover, TCZ can be used either in combination
with methotrexate (MTX) or as a biological monotherapy. The latter approach is supported by
data from several clinical trials (SATORI, SAMURAI and AMBITION studies) showing that
TCZ was more efficacious than MTX in patients who had failed previous treatment with MTX
or biological agents [3–5].
Although TCZ monotherapy has been shown to be a viable option, both in clinical trials [6]
and in daily practice, recent data indicate that the efficacy of TCZ is even greater when it is ad-
ministered in combination with MTX. Two studies compared the addition of TCZ with MTX
(combination or “add-on” strategy) with switching fromMTX to TCZ monotherapy (MTX
withdrawal). In the non-inferiority SURPRISE study, as well as in the ACT-RAY study, similar
American College of Rheumatology (ACR) 70 responses were observed in both groups at
6 months [7,8]. However, 12-month data from both studies revealed higher rates for 28-joint dis-
ease activity score (DAS28) remission and radiographic non-progression when TCZ andMTX
were used in combination [9,10]. More recently, Kojima et al.[11] published an observational
multicenter study investigating predictive baseline factors in remission in patients with active RA
treated with TCZ in clinical practice. The authors observed that, in patients with high baseline
disease activity (DAS28> 5.1), concomitant MTX use was associated with increased odds of re-
mission (adjusted odds ratio [OR] at baseline = 2.54 [95% CI 1.11, 5.83]), whereas no association
was observed in patients with low to moderate baseline disease activity (DAS28 5.1).
Based on these data, the European League against Rheumatism (EULAR) continues to rec-
ommend the combination therapy of TCZ with a DMARD due to its superior long-term clini-
cal and radiographic outcomes [12]. However, in patients for whomMTX is contraindicated or
poorly tolerated, a viable option is to use TCZ monotherapy or to use it in combination with
other DMARDs, despite the lack of specifically designed, randomized clinical trials supporting
these alternative strategies. In this context, observational data regarding the effectiveness and
safety of such treatment combinations can provide a lower, but still useful, level of evidence.
One treatment option with insufficient supportive evidence is the combination of TCZ with
leflunomide (LEF). The efficacy of LEF in the treatment of moderate to severe RA has been
shown in several randomized trials, and as a single agent, its efficacy is comparable to that of
MTX [13]. In addition, prospective case series and cohort studies have confirmed the safety
and effectiveness of the off-label combination of LEF plus anti-TNF agents [14,15] and LEF
plus rituximab [16–18]. Detailed information regarding the efficacy and safety of TCZ in com-
bination with LEF has not been published.
Therefore, the aim of the present study was to compare the effectiveness and safety at 6
months of TCZ in combination with either MTX or LEF in the treatment of patients with
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active RA and an inadequate response to anti-TNF agents or traditional DMARDs in an
observational setting.
Materials and Methods
The sample included all patients with active RA (all of whom met the American College of
Rheumatology (ACR) classification criteria for RA) [19] who were routinely treated from Janu-
ary 2009 to November 2012 with TCZ+MTX or TCZ+LEF at four different Spanish hospitals.
A retrospective analysis of prospectively collected data was performed.
In accordance with the guidelines of our institutional ethics committee, formal approval for
this study was not required. The local ethics committee agreed that the findings in this report
were based on normal clinical practice and were therefore suitable for dissemination. Informed
consent was not obtained from the patients, but their clinical records and information were
anonymized prior to analysis.
This study was conducted in accordance with the principles of the Declaration of Helsinki
and the International Conference for Harmonization.
During the study period, 91 patients were identified; among them, 62 received TCZ+MTX
and 29 received TCZ+LEF. Eighty-one patients received treatment for at least 6 months; in the
remaining 10 patients, treatment was discontinued early due to serious adverse events.
TCZ was administered every 4 weeks at a typical dose of 8 mg/kg and could be adapted
according to EULAR and local recommendations [20,21]. The average dose of MTX was
16.1 ± 6.0 mg/week (median 15.0 mg/week; range 7.5–25). The LEF dose was 10 and
20 mg/day orally in 5 and 24 patients, respectively; the majority of these 29 patients had pre-
viously experienced an inadequate response (N = 9) or intolerance (N = 20) to MTX. Sixty
(66%) patients were also receiving concomitant low-dose oral glucocorticoid treatment
(10 mg/day of prednisone or equivalent). Increased or decreased doses of prednisone and
DMARD were allowed at the discretion of the referring physician.
Baseline data collected at the time of TCZ prescription included the following: age, gender,
disease duration, presence of rheumatoid nodules, evidence of erosions (established by hand
and foot radiographs), presence of extra-articular manifestations, details of past and present
anti-rheumatic therapies (DMARDs, steroids, and previous biological agents used), erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), and the serological status for rheumatoid
factor (RF) and anti-citrullinated peptide antibodies (ACPA). In addition, we assessed disease
activity using the patient global assessment, the swollen and tender joint count in 28 joints, the
DAS28 based on the erythrocyte sedimentation rate (DAS28-ESR), the Simplified Disease Ac-
tivity Index (SDAI), the Clinical Disease Activity Index (CDAI), and a health assessment ques-
tionnaire (HAQ). The same items for disease activity were recorded after 6 months of
treatment.
A comparative study between the 2 combination treatments (TCZ+MTX and TCZ+LEF)
was performed at the 6-month follow-up considering 3 outcomes: the improvement in RA dis-
ease activity, the evolution of functional disability, and the tolerability and side effect profile.
We examined RA disease activity using the DAS28-ESR, SDAI, and CDAI. The primary
outcome measure of the study was the rate of remission, which was defined as a
DAS28-ESR< 2.6 at 6 months. Secondary efficacy endpoints included the percentage of pa-
tients with low disease activity (defined as DAS28-ESR 3.2); the percentage of patients who
fulfilled the ACR 50 response criteria; the SDAI ( 3.3), CDAI ( 2.8) and 2010 ACR-EULAR
criteria (Boolean definition) remission rates; and the EULAR response criteria (32). A good re-
sponse was defined as a significant decrease in the DAS28-ESR score (> 1.2) and a low level
of disease activity ( 3.2). A non-response was defined as a decrease of 0.6 or a decrease of
Tocilizumab with either MTX or LEF
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0.6–1.2 with a DAS28 score> 5.1. Any scores between these limits were regarded as indicative
of moderate responses. The progression of functional disability was measured by the change
from baseline on the disability index of the Stanford HAQ.
For the efficacy analysis, we considered only the 81 patients who were assessed after
6 months of TCZ treatment. For the safety analysis, we included the 10 patients for whom treat-
ment had to be discontinued due to serious adverse events during the first 6 months (N = 91).
Statistical Analysis
Statistical analysis was performed using SAS 9.1.3 statistical software. Continuous data are de-
scribed as the mean ± standard deviation (SD) or median (minimum, maximum), and categor-
ical variables are presented as the number of cases with percentages. Continuous variables were
compared using Student's t-test or the median test. Categorical variables were analyzed by the
Chi-square test or the Fisher exact test when the expected values were less than 5 and by calcu-
lating the 95% confidence intervals (CI) for differences between proportions using New-
combe’s method. Statistical significance was defined as p< 0.05.
Results
Patient Baseline Characteristics and Clinical Efficacy
Of the 91 patients included in this study, only 81 completed at least 6 months of treatment
with TCZ; of these patients, 55 received TCZ+MTX and 26 received TCZ+LEF. The patient
and treatment characteristics at baseline are shown in Table 1. There were no significant differ-
ences in baseline disease characteristics between the treatment groups. Most of the patients had
long-standing refractory RA, and all of the patients had a history of failed treatment with at
least 1 DMARD (median 2; range 1–7). Fifty-four patients (67%) received TCZ after the failure
of at least one biological therapy (2.18 ± 1.1; 1–6). Primary or secondary inefficacy, rather than
the development of side effects, was the reason for biological failure in most cases.
During the follow-up in these first 6 months, there were no differences between groups in
the mean dose of concomitant prednisone treatment (5.6 ± 2.1 mg in the TCZ+MTX group
versus 5.4 ± 1.8 mg in the TCZ+LEF group) or in the percentage of patients with a reduction of
the TCZ dose due to adverse events [TCZ+MTX: 4 (6.4%) versus TCZ+LEF: 2 (6.8%)]. All of
the patients were maintained on a stable dose of MTX or LEF until the end of the 6-month
observation period.
Table 2 shows the response rates after 6 months of therapy. Overall, DAS28 remission
(DAS28-ESR< 2.6) was achieved in 43% of the patients, low disease activity (DAS283.2) in
66%, and EULAR response in 91% (62% showed a good response and 29% a moderate re-
sponse). There were no significant differences between the combination therapies in the pro-
gression of RA disease activity or functional disability (HAQ).
The level of improvement in disease activity showed little variation between the two groups:
during the first 6 months after treatment initiation, DAS28 improved by 2.23 ± 1.38 with
TCZ+MTX and by 2.17 ± 1.43 with TCZ+LEF. The percentage of patients with remission, as
defined by DAS28-ESR (< 2.6), SDAI ( 3.3), CDAI ( 2.8) and 2010 ACR-EULAR criteria
(Boolean definition), was similar between the treatment strategies. The EULAR good and mod-
erate response rates, the number of patients with low disease activity (DAS28-ESR< 3.2), and
the percentage of patients who achieved an ACR 50 response did not differ significantly. The
levels of improvement in the acute-phase reactants (ESR and CRP) were also comparable.
Functional disability improved during the first 6 months after treatment initiation, without
significant differences in HAQ reductions between the treatment groups: HAQ improved by
0.64 with TCZ+MTX and by 0.62 with TCZ+LEF. However, treatment with TCZ was
Tocilizumab with either MTX or LEF
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suspended in 7 patients due to primary inefficacy after 6 months, including 4 patients in the
TCZ+MTX group (7%) and 3 in the TCZ+LEF group (12%).
Among the patients in the TCZ+LEF group, there were no differences in efficacy between
the 10 versus the 20 mg dosage of LEF.
Tolerability and Safety
An overview of the treatment safety is presented in Table 3. In total, 49 patients (54%) experi-
enced one or more adverse events. Serious adverse events requiring TCZ discontinuation be-
fore 6 months of treatment occurred in 11% (7/62) of the TCZ+MTX patients and in 10% (3/
29) of the TCZ+LEF patients. In the TCZ+MTZ group, the discontinuations included 2 cases
of infusion reaction and 5 serious infections (2 cases of septic arthritis, 2 cases of acute pelvic
inflammatory disease/salpingitis, and 1 case of diverticulitis). In the TCZ + LEF group, 1 case
developed a TCZ-induced psoriasiform rash and 2 cases developed infections (1 each with
Table 1. Baseline Characteristics at Initiation of Tocilizumab Therapy in Patients Completing 6 Months of Treatment.
TCZ + MTX TCZ + LEF P Value
Number of patients 55 26
Women/men 51/4 23/3 0.67
Age, years 56 ± 11.5 59 ± 12.7 0.29
Disease duration, years 12 (1, 41) 9 (2.5, 32) 0.08
Positive rheumatoid factor 40 (73%) 20 (77%) d = −4.20 (95% CI −21.89, 17.25),
p = 0.79
Positive ACPA antibodies 39 (71%) 20 (77%) d = −6.01 (95% CI −23.77, 15.59),
p = 0.76
Rheumatoid nodules 13 (24%) 6 (23%) d = 0.56 (95% CI −20.56, 18.07),
p = 0.95
Erosions in the peripheral joints 43 (78%) 19 (73%) d = 5.10 (95% CI −13.12, 26,22),
p = 0.82
Systemic extra-articular manifestations 15 (27%) 7 (27%) d = 0.35 (95% CI −21.26, 18.86),
p = 0.97
Tender joint count/28 9.2 ± 5.3 8.6 ± 5.5 0.63
Swollen joint count/28 6.5 ± 4.5 6 ± 4.7 0.64






CDAI 25 (12, 55) 23 (14, 44) 0.39
HAQ (0–3) 1.61 ± 0.60 1.63 ± 0.65 0.89
ESR (mm/h) 34 (2, 137) 43 (8, 104) 0.58
CRP (mg/l) 9.4 (0.1,
117.4)
12.5 (0.6, 194) 0.42
Number of previous DMARDs used 2 (1, 7) 2 (1, 6) 0.21
Tocilizumab as a ﬁrst-line biological therapy 18 (33%) 9 (35%) d = −1.89 (95% CI −23.94, 18.23)
p = 0.86
Number of previous biological agents used 2 (0, 5) 2 (0, 4) 0.65
Reason for discontinuation: primary or secondary inefﬁcacy (%) / development
of side effects (%)
69% / 31% 73% / 27% 0.64
Low-dose oral glucocorticoid treatment 41 (75%) 19 (73%) d = 1.47 (95% CI −16.96, 22.92),
p = 0.88
Results are presented as the mean ± standard deviation, median (minimum, maximum), or number of cases with percentages. CDAI: clinical disease
activity index; CI: conﬁdence interval; d: difference; LEF: leﬂunomide; MTX: methotrexate; SDAI: simpliﬁed disease activity index.
doi:10.1371/journal.pone.0123392.t001
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endocarditis and diverticulitis). The rates of serious adverse events per 100 patient-years were
similar in the two groups: 23.5 in TCZ+MTX versus 21.4 in TCZ+LEF.
Minor adverse events occurred in 40% (25/62) and 48% (14/29) of the patients treated with
TCZ+MTX and TCZ+LEF, respectively. Such events included transient neutropenia, an eleva-
tion of lipid parameters or liver enzymes (> 1 to 3 x ULN, leading to a reduction of the TCZ
dose to 4 mg/kg until normalization of ALT or AST in 6 patients), and non-serious infections.
No cases of malignancy or death occurred.
Among the patients in the TCZ+LEF group, there were no differences in side effects be-
tween the 10 versus the 20 mg dosage of LEF.
Discussion
The present results indicate that LEF is an effective and safe (equivalent) alternative to MTX as
a concomitant treatment with TCZ. LEF is an immunomodulatory drug that may exert its ef-
fects by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH),
which plays a key role in pyrimidine synthesis [13]. LEF has demonstrated effectiveness for the
treatment of RA and is used as an alternative when MTX is contraindicated or poorly tolerated.
LEF can be administered as monotherapy or in combination with biological agents. Indeed,
prospective case series and cohort studies have confirmed the safety and effectiveness of the
off-label combination of LEF plus anti-TNF agents [14,15] and LEF plus rituximab [16–18].
At present, detailed information regarding the efficacy and safety of TCZ in combination
with LEF has not been published. The multicenter clinical trial TOWARD (TCZ in combina-
tion with traditional DMARD therapy) [22], together with a majority of patients treated with
MTX, included 387 patients treated with chloroquine/hydroxychloroquine, sulfasalazine, LEF
Table 2. Treatment Response Rates after 6 Months of Combination Therapy.
TCZ + MTX TCZ + LEF P Value
N = 55 N = 26
DAS28-ES 3.27 ± 1.42 3.23 ± 1.51 0.90
Change in DAS 28 −2.23 ± 1.38 −2.17 ± 1.43 0.85
Swollen joint count/28 1.87 ± 3.2 1.82 ± 2.8 0.87
DAS28-ESR remission rate (< 2.6) 24 (44%) 11 (42%) d = 1.33 (95% CI −21.07, 22.60); p = 0.91
DAS28-ESR LDAS (< 3.2) 37 (67%) 17 (65%) d = 1.89 (95%CI −18.23, 23.94); p = 0.86
SDAI remission rate ( 3.3) 14 (25%) 7 (27%) d = −1.47 (95% CI −22.92, 16.96); p = 0.88
CDAI remission rate ( 2.8) 14 (25%) 6 (23%) d = 2.38 (95% CI −18.91, 19,99); p = 0.81
ACR50 responders 24 (44%) 11 (42%) d = 1.33 (95% CI −21.07, 22.60); p = 0.91
EULAR response
Good + moderate responders 51 (93%) 23 (88%) d = 4.27 (95% CI −8.25, 22.25); p = 0.83
Good 34 (62%) 16 (62%) d = 0.28 (95% CI −20.49, 22.58); p = 0.98
Moderate 17 (31%) 7 (27%) d = 3.99 (95% CI −17.92, 22.61); p = 0.91
None 17 (31%) 3 (12%) d = −4.27 (95% CI −22.25, 8.25); p = 0.83
ACR/EULAR Boolean remission rate 10 (18%) 5 (19%) d = −1.05 (95% CI −21.34, 15.16); p = 0.90
HAQ Change in HAQ −0.64 (−3, 1) −0.62 (−2. 2 0.91
ESR (mm/h) 9.41 ± 8.23 9.59 ± 8.89 0.92
CRP (mg/l) 2.1 ± 1.9 2.5 ± 1.8 0.37
Results are presented as the mean ± standard deviation, median (minimum, maximum), or number of cases with percentages. CDAI: clinical disease
activity index; CI: conﬁdence interval; d: difference; LEF: leﬂunomide; MTX: methotrexate; SDAI: simpliﬁed disease activity index.
doi:10.1371/journal.pone.0123392.t002
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(N = 97), parenteral gold salts, or azathioprine. At week 24, TCZ in combination with any of
the study DMARDs resulted in a higher proportion of ACR 20/50/70 responders than did
DMARDs plus placebo, with no apparent differences in efficacy and safety among the different
DMARDs. More recently, Burmester et al. presented the results of the German multicenter,
prospective, non-interventional TAMARA study, which was designed to evaluate the effective-
ness and safety of TCZ treatment for RA in routine outpatient settings [23]. This cohort
also included a non-specified number of patients who were receiving LEF treatment. After
6 months of treatment, patients with concomitant LEF treatment did not differ from those who
were treated with MTX with regard to efficacy parameters, suggesting that LEF might represent
a suitable DMARD for combination therapy. However, these two previous publications did
not describe the specific side effects and clinical efficacy parameters associated with the
LEF+TCZ combination.
The present study has several limitations that are inherent to the analysis of observational
data (it is not prospective or randomized) and the relatively small sample size. Almost all of the
patients who were treated with LEF had previously inadequate responses or intolerance to
MTX, which could result in selection bias or confounding by indication. However, confound-
ing by indication would most likely bias the results toward the null hypothesis because LEF was
prescribed to patients who were more difficult to treat, with poor tolerance or with failure to re-
spond to MTX. Thus, the data represent outcomes from realistic clinical practice settings with
the strength of no potential corporate bias.






N = 62 N = 29
Total patients with  1 adverse event 32 (52%) 17 (59%) d = −7.1 (95% CI −27.00, 14.52);
p = 0.65
Number of patients with serious adverse events leading to discontinuation of
TCZ
7 (11%) 3 (10%) d = 0.95 (95% CI −16.08, 13.21);
p = 0.89
Serious Infections 5 (8%) 2 (7%) d = 1.17 (95% CI −14.58, 11,86);
p = 0.84
Infusion reactions 2 (3.2%) 0 (0%) d = 3.23 (95% CI −8.7, 11.02); p = 0.83
Psoriasis onset 0 (0%) 1 (3.4%) d = −3.45 (95% CI −17.18, 3.04); p = 0
0.69
Number of patients with  1 non-serious adverse event 25 (40%) 14 (48%) d = −7.95 (95% CI −28.61, 13.02);
p = 0.62
Neutropenia 3 (5%) 2 (7%) d = −2.06 (95% CI −17.46, 7.75);
p = 0.68
Elevated liver enzymes 5 (8%) 5 (17%) d = −9.18 (95% CI −27.08, 4.33);
p = 0.34
Elevation in lipid parameters 13 (21%) 6 (21%) d = 0.28 (95% CI −19,26, 16.21);
p = 0.97
Non-serious infections 5 (8%) 2 (7%) d = 1.17 (95% CI −14.58, 11,86);
p = 0.84
Malignancies 0 (0%) 0 (0%)
Deaths 0 (0%) 0 (0%)
Results are presented as the number of cases with percentages. CI: conﬁdence interval; d: difference; LEF: leﬂunomide; MTX: methotrexate.
†Includes patients for whom treatment was interrupted before 6 months due to serious adverse events (N = 10).
doi:10.1371/journal.pone.0123392.t003
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In conclusion, according to EULAR recommendations, a DMARD in combination with a
biotherapy is the reference treatment. MTX is the cornerstone of combination therapy and
continues to be the first choice. However, MTX must be replaced by another DMARD in some
patients due to inefficacy or intolerance. Our data support the argument that LEF is an alterna-
tive when MTX is contraindicated, providing comparable effectiveness and safety profiles.
These findings are consistent with two previous studies that did include LEF+TCZ groups but
did not provide detailed information about this combination. However, due the uncontrolled
nature of our study, the potential for bias, and the small sample size, the clinical significance of
the present findings is limited. Further controlled trials are warranted to confirm the long-term
safety and efficacy of TCZ combination therapy with LEF for the treatment of RA.
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